SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-112406
Filing Date
2020-10-06
Accepted
2020-10-06 07:14:49
Documents
15
Period of Report
2020-10-06
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2032537d1_8k.htm   iXBRL 8-K 33401
2 EXHIBIT 99.1 tm2032537d1_ex99-1.htm EX-99.1 19457
3 EXHIBIT 99.2 tm2032537d1_ex99-2.htm EX-99.2 241389
7 GRAPHIC tm2032537d1_ex99-1img001.jpg GRAPHIC 9690
  Complete submission text file 0001104659-20-112406.txt   552166

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA axgt-20201006.xsd EX-101.SCH 3239
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE axgt-20201006_lab.xml EX-101.LAB 34591
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE axgt-20201006_pre.xml EX-101.PRE 22708
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2032537d1_8k_htm.xml XML 3818
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 201225561
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences